Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.
Results from new clinical trials signal a role for the immunotherapy Opdivo in the treatment of gastric cancer and heavily pretreated esophageal cancer.